NCT05258032

Brief Summary

Rare ocular diseases (ROD) are a heterogeneous group of ocular diseases that affect very few people and, generally, for which no tretament is available. An important subgroup of these diseases are inherited retinal degenerations. In this study we focus on understanding the natural history of different ROD that affect the posterior segment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 24, 2021

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

February 17, 2022

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 28, 2022

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 24, 2024

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

November 24, 2025

Completed
Last Updated

March 15, 2022

Status Verified

February 1, 2022

Enrollment Period

3 years

First QC Date

February 17, 2022

Last Update Submit

February 28, 2022

Conditions

Keywords

Retinitis pigmentosaStargardt's disease 1Best diseasePattern Dystrophy of MaculaChoroideremia

Outcome Measures

Primary Outcomes (1)

  • Change in best corrected visual acuity

    Change from baseline in BCVA

    Year 2 as compared to baseline

Secondary Outcomes (2)

  • Change in mean macular sensitivity

    Year 2 as compared to baseline

  • Change in retinal thickness

    Year 2 as compared to baseline

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with a ROD affecting the posterior segment of the eye

You may qualify if:

  • Male or female 18 years or older with a diagnosis of a ROD affecting the posterior segment
  • Patients able to undergo all required ophthalmic exams
  • Patients able and willing to sign an informed consent

You may not qualify if:

  • Patients with other concomitant posterior segment disorders
  • Patients taking drugs known to affect the retina and/or optic nerve
  • Patients that underwent an intraocular surgery (aside from phacoemulsification with intraocular lens implantation), corneal or glaucoma surgery
  • Patients who have participated in the past 12 months or that are currently participating in clinical trials for an ocular disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institut de la màcula

Barcelona, 08022, Spain

RECRUITING

MeSH Terms

Conditions

Retinitis PigmentosaStargardt DiseaseVitelliform Macular DystrophyChoroideremia

Condition Hierarchy (Ancestors)

Eye Diseases, HereditaryEye DiseasesRetinal DystrophiesRetinal DegenerationRetinal DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesMacular DegenerationChoroid DiseasesUveal DiseasesGenetic Diseases, X-Linked

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

February 17, 2022

First Posted

February 28, 2022

Study Start

November 24, 2021

Primary Completion

November 24, 2024

Study Completion

November 24, 2025

Last Updated

March 15, 2022

Record last verified: 2022-02

Locations